Complete response to immune checkpoint inhibitors-based therapy in advanced renal cell carcinoma patients. A meta-analysis of randomized clinical trials-Reference-Cited by-同舟云学术

Complete response to immune checkpoint inhibitors-based therapy in advanced renal cell carcinoma patients. A meta-analysis of randomized clinical trials

Published:2020-10 Issue:10 Volume:38 Page:798.e17-798.e24
ISSN:1078-1439
Container-title:Urologic Oncology: Seminars and Original Investigations
language:en
Short-container-title:Urologic Oncology: Seminars and Original Investigations

Author:

Iacovelli R.,Ciccarese C.,Schutz F.A.,Tortora G.,de Velasco G.

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference37 articles.

1. Systemic therapy for metastatic renal-cell carcinoma;Choueiri;N Engl J Med,2017

2. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy;Fyfe;J Clin Oncol,1995

3. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer;Atkins;Clin Cancer Res,2005

4. A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a cytokine working group (CWG) study;Dandamudi;J Immunother,2013

5. The high-dose Aldesleukin «Select» trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma;McDermott;Clin Cancer Res,2015

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Managing Metastatic Renal Cell Carcinoma after Progression on Immunotherapy;Hematology/Oncology Clinics of North America;2023-10

2. Metastatic pulmonary pleomorphic carcinoma replaced by a granulomatous lesion after spontaneous regression and PD-1 blockade-induced regression: can epithelioid granuloma be a histological hallmark of cancer immunity?;Immunological Medicine;2023-03-22

3. Targeting hypoxia-inducible factor pathways in sporadic and Von Hippel-Lindau syndrome-related kidney cancers;Critical Reviews in Oncology/Hematology;2022-08

4. Current evidence for second-line treatment in metastatic renal cell carcinoma after progression to immune-based combinations;Cancer Treatment Reviews;2022-04

5. Immunotherapy in pancreatic cancer—an emerging role: a narrative review;Chinese Clinical Oncology;2022-02